Lucite deal tombstone marking a registered direct offering of stock by AlloVir. The clinical-stage cell therapy firm is based in Waltham, Massachusetts. (22AZH231)
Whether you’re celebrating a funding round, research collaboration, FDA-approval, or commemorating a deal in the biotech space, you’ll find inspiration in the custom designs below.
Lucite deal tombstone marking a registered direct offering of stock by AlloVir. The clinical-stage cell therapy firm is based in Waltham, Massachusetts. (22AZH231)
Lucite tombstone recognizing the acquisition of GeneTx BioTherapeutics. GeneTx has focused on a therapy for Angelman syndrome, a rare neurogenic disease. (22ALJ280)
Lucite deal toy commemorating the acquisition of CytoSMART, a Dutch firm specializing in live-cell imaging analysis. The acquirer, Axion BioSystems, is an Atlanta-based life sciences company. (22AZH106)
Custom financial tombstone recognizing a direct offering of common stock by Salarius Pharmaceuticals. The Houston-based firm develops cancer therapies. (22AJH070)
Lucite deal toy recognizing the acquisition of Cincinnati-based Advanced Testing Laboratory. ATL provides research and development services in such areas as life science, product safety, and analytical chemistry. (22AJH077)
Lucite deal toy celebrating a license option agreement between Ironwood Pharmaceuticals and COUR, a biotech firm. The agreement centers on COUR’s therapy for PBC, a rare autoimmune disease affecting the liver.
(22ALJ081)Crystal deal toy celebrating the initial public offering on the Australian Securities Exchange (ASX) of Radiopharm Theranostics. The Sydney-based company develops radiopharmaceutical drugs and treatments for cancer.
(21ALJ553)Beginning on this page, you’ll find galleries with over 90 images of financial tombstones and deal toys from the biotech and life sciences space. You’ll find a number of custom designs playing off visual elements commonly associated with this space, including DNA strands, pills, lab beakers, periodic tables, as well as ones incorporating actual drug vials.
As you might also expect, you’ll see a number of deal toys involving internationally recognized firms and players. These include Takeda Pharmaceutical, Horizon Therapeutics, Gilead Sciences, Roche, Neurocrine, and Bayer. You’ll see as well tombstones commemorating transactions common to this sector involving these and other firms: joint ventures, licensing deals, and development and commercialization agreements.
But you’ll also notice a number of deals commemorated here that may involve far less familiar firms. These include the acquisition of a Dutch company focused on live-cell imaging analytics, and one of an Illinois-based gene therapy firm devoted to the treatment of a rare genetic disorder; the initial public offering of an Australian developer of radiopharmaceutical cancer therapies, and the IPO of a Norwegian biotech making use of marine compounds such as herring roe extract; early-stage funding for a Philadelphia gene engineering startup, and the IPO of an Israeli firm focused on medical applications for lipid-based compounds.
You’ll also notice in these galleries designs not related to any financial transaction. These celebrate a range of awards and employee recognition pieces honoring successful clinical trials, Food and Drug Administration (FDA) and New Drug Application (NDA) submissions, research collaborations and partnerships, and product development milestones.
"*" indicates required fields
